

Call: 8th Call - JPIAMR-VRI Network Call 2018

Title: TRANSLOCATION-transfer

Acronym: TT

Network composition

Type: C – coordinator P - participant	Name	Institute	Country
C	Mathias Winterhalter	Jacobs University Bremen	Germany
P	Philip Gribbon	Fraunhofer-Institut für Molekularbiologie und Angewandte Oekologie	Germany
P	Kim Wes	The Pew Charitable Trusts	USA
P	Paolo Ruggerone	University of Cagliari	Italy
P	Miguel Viñas	University of Barcelona	Spain
P	Isabelle Schalk	Biotechnologie et Signalisation Cellulaire	France
P	Françoise van Bambeke	Université catholique de Louvain	Belgium
P	Helen I. Zgurskaya	University of Oklahoma,	USA
P	Emad Tajkhorshid	Beckman Institute for Advanced Science and Technology,	USA
P	Derek S. Tan	Memorial Sloan Kettering Cancer Center	USA
P	Olga Genilloud	Fundación MEDINA	Spain
P	Nevine Sobhy Fam	Theodor Bilharz Research Institute/Affiliated to Egyptian Ministry Higher Education Scientific Research	Egypt
P	Haim Barr	The Weizmann Institute of Science	Israel
P	Wolfgang Fecke	EU-OPENSREEN ERIC	Germany
P	Jacek Lukasz Kolanowski	Institute of Bioorganic Chemistry Polish Academy of Sciences (IBCH PAS)	Poland
P	Jean-Marie Pagès	INSERM	France
P	Ruth Brenk	University of Bergen	Norway
P	Thilo Köhler	University Hospitals of Geneva and University of Geneva	Switzerland
P	Aigars Jirgensons	Latvian Institute of Organic Synthesis	Latvia
P	Esin Aki-Yalcin	Ankara University	Turkey
P	Petr Džubák	Palacky University Olomouc	Czech Republic
P	Päivi Tammela	University of Helsinki	Finland

Chosen focal area

- Develop a Communication and Knowledge Translation Strategy
- Develop a Partnerships Strategy to ensure key stakeholders, including industry and policy makers, and other networks are engaged and coordinate the alignment of other funded Networks
- Develop a map of other funded Networks (e.g. current information on expertise, fields of interest, demographics, available technologies and resources)
- Alignment of research capacities within the early antibiotic drug development

Network summary

There is an urgent need for discovery and development of new drugs to combat multi-resistant organisms. The search for new drugs is cumbersome, particularly because the current business model for antibiotics in the pharmaceutical industry has been stalled because of the poor return on investment. In response to the pharmaceutical industry stepping back from antibiotic discovery, multiple public efforts, including the JPIAMR and IMI ND4BB, as well as the efforts of Biomedical Science (BMS) European Research Infrastructures community have stepped in to fill the gap.

In this project, the TT network will set up a knowledge sharing network, Translocation-Transfer bringing together experts from with two major publically funded programs, with the goal to improve the process of academically driven antibiotic drug discovery by capitalising on recently gained insights into a key bottleneck in anti-bacterial research, namely how compound penetration properties determine efficacy and resistance properties. Three existing communities forming the TT network are:

- 1) the partners associated with the multinational program Translocation (www.translocation.eu), part of IMI ND4BB;
- 2) partner sites from EU-OPENSSCREEN, the European Research Infrastructure for chemical biology and screening (www.eu-openscreen.eu);
- 3) partners from the wider global community working on AMR issues and research.

Translocation (1/2013-6/2018) was one of the largest antibiotic research programs in the world specifically devoted to understanding and to devising ways of increasing antibiotic penetration into bacteria. EUOPENSSCREEN began operations in April 2018 and from 2019 onwards will run some 50 chemical biology and academic drug discovery projects per year, across a network of 25 screening sites, based in eight European countries on behalf of users from across Europe. It is anticipated that at least 20% of EU-OPENSSCREEN projects will involve antibiotic drug discovery element. The initial goal of the TT network will be to transfer knowledge between Translocation and EU-OPENSSCREEN to fully incorporate compound permeation and efflux considerations into academic antibiotic drug discovery. We have the active participation of the Pew Charitable Trust, which will contribute to the long-term systematic dissemination of findings from the co-funded funded Translocation project to help academic antibiotic drug discovery efforts on a global scale.